Summit Therapeutics Inc.
SMMT
Rangering i aksjer
#1661
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering,... Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Aksjekurs
$16.14
Sist synkronisert: 2026-10-20
Markedsverdi
$12.87B
Endring (1 dag)
3.65%
Endring (1 år)
-13.88%
Land
US
Handel Summit Therapeutics Inc. (SMMT)
Kategori
Healthcare
Historikk for aksjesplitt for Summit Therapeutics Inc. (SMMT)
Aksjen Summit Therapeutics Inc. (symbol: SMMT) har gjennomgått totalt 0 aksjesplitt.
Den nyeste splittelsen skjedde Oct 21, 2026.
Én SMMT-aksje kjøpt før Oct 21, 2026 tilsvarer i dag 0 SMMT-aksjer.
Den nyeste splittelsen skjedde Oct 21, 2026.
Én SMMT-aksje kjøpt før Oct 21, 2026 tilsvarer i dag 0 SMMT-aksjer.
Liste over aksjesplitt
| År | Splitt | Multiplikator | Kumulativ multiplikator |
|---|---|---|---|
| Ikke nok data for de angitte datoene. | |||
Aksjesplitt for lignende selskaper eller konkurrenter
| Selskap | Antall aksjesplitt | Kumulativ multiplikator | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
